FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1999949526> ?p ?o ?g. }

• W1999949526 endingPage "307" @default.
• W1999949526 startingPage "298" @default.
• W1999949526 abstract "Oral treatment of osteoporosis with bisphosphonates relies on compliance, the absorption being low and suppressed by simultaneous food intake. Intravenous (IV) treatment with an aminobisphosphonate, pamidronate (once every 3 months) was effective, but required infusions. Ibandronate, a new very potent aminobisphosphonate, can be administered safely as an IV bolus injection, and therefore offers an interesting alternative suitable for outpatient treatment.To test the efficacy of this bolus IV treatment in postmenopausal osteoporosis in randomized partly double-blind, placebo controlled study, 125 postmenopausal women (mean age, 64 years) with osteoporosis (bone mineral density [BMD] < -2.5 SD T score) received a placebo or ibandronate (0.25, 0.5, 1, or 2 mg) every 3 months. All patients received 1 g calcium/day. BMD, in g/cm2, was measured by dual-energy x-ray absorptiometry at all standard sites.Lumbar spine BMD (L2 to L4) did not change (0.85%) in the placebo group, but increased by 2.4%, 3.5%, 3.7%, and 5.2% at 12 months for dose-ranging groups (no significant differences among ibandronate groups). The increase was statistically significantly different from placebo for the 0.5 mg (P < 0.006), 1 mg (P < 0.004), and 2 mg (P < 0.001) group, whereas with 0.25 mg no significant differences occured. After 1 year there were no significant changes in BMD compared with placebo at the femoral neck, Ward's triangle, and distal forearm. Total hip and trochanter BMD increased significantly, by 1.8% and 2.9% for total hip and by 2.7% and 4.2% for trochanter in the 1 and 2 mg group, respectively. Urinary excretion of C-telopeptide and N-telopeptide decreased after 1 month in all ibandronate groups, with a clear dose dependency. Three months after the first injection of 2 mg ibandronate there was still a significant reduction in these markers of bone resorption. Osteocalcin decreased progressively and dose dependently over time. There was a correlation between the decrease in C-telopeptide measured after 1 month and the increase in lumbar spine BMD after 1 year (n = 115, r = -0.26, P < 0.012). Ibandronate therapy proved to be safe. There was no significant difference in the overall number of adverse events in the ibandronate groups compared with the placebo group. Considering specific adverse events, no dose dependency and difference to placebo could be observed apart from acute reactions that occurred in 7% of the patients.Treatment of postmenopausal osteoporosis by interval IV bolus injections of the bisphosphonate ibandronate was safe and effective in increasing BMD through a dose-dependent inhibition of bone resorption. The high potency of ibandronate allows 3-month interval bolus IV injections as a new therapeutic approach with optimal compliance." @default.
• W1999949526 created "2016-06-24" @default.
• W1999949526 creator A5006902955 @default.
• W1999949526 creator A5007564488 @default.
• W1999949526 creator A5011404558 @default.
• W1999949526 creator A5038552190 @default.
• W1999949526 creator A5063351053 @default.
• W1999949526 creator A5081452175 @default.
• W1999949526 creator A5090577453 @default.
• W1999949526 date "1997-10-01" @default.
• W1999949526 modified "2023-09-26" @default.
• W1999949526 title "Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis" @default.
• W1999949526 cites W1883130365 @default.
• W1999949526 cites W1966703501 @default.
• W1999949526 cites W1968418396 @default.
• W1999949526 cites W1972641924 @default.
• W1999949526 cites W1973406329 @default.
• W1999949526 cites W1987901471 @default.
• W1999949526 cites W1995580211 @default.
• W1999949526 cites W1996898338 @default.
• W1999949526 cites W2006021879 @default.
• W1999949526 cites W2012291531 @default.
• W1999949526 cites W2027671535 @default.
• W1999949526 cites W2050352060 @default.
• W1999949526 cites W2062011037 @default.
• W1999949526 cites W2065399719 @default.
• W1999949526 cites W2070815981 @default.
• W1999949526 cites W2073141330 @default.
• W1999949526 cites W2074704125 @default.
• W1999949526 cites W2085840490 @default.
• W1999949526 cites W2108875090 @default.
• W1999949526 cites W2131993528 @default.
• W1999949526 cites W2336517627 @default.
• W1999949526 cites W2336678594 @default.
• W1999949526 cites W2337197041 @default.
• W1999949526 cites W2599867508 @default.
• W1999949526 doi "https://doi.org/10.1016/s0002-9343(97)00249-0" @default.
• W1999949526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9382122" @default.
• W1999949526 hasPublicationYear "1997" @default.
• W1999949526 type Work @default.
• W1999949526 sameAs 1999949526 @default.
• W1999949526 citedByCount "182" @default.
• W1999949526 countsByYear W19999495262012 @default.
• W1999949526 countsByYear W19999495262013 @default.
• W1999949526 countsByYear W19999495262014 @default.
• W1999949526 countsByYear W19999495262015 @default.
• W1999949526 countsByYear W19999495262016 @default.
• W1999949526 countsByYear W19999495262017 @default.
• W1999949526 countsByYear W19999495262020 @default.
• W1999949526 countsByYear W19999495262021 @default.
• W1999949526 countsByYear W19999495262022 @default.
• W1999949526 crossrefType "journal-article" @default.
• W1999949526 hasAuthorship W1999949526A5006902955 @default.
• W1999949526 hasAuthorship W1999949526A5007564488 @default.
• W1999949526 hasAuthorship W1999949526A5011404558 @default.
• W1999949526 hasAuthorship W1999949526A5038552190 @default.
• W1999949526 hasAuthorship W1999949526A5063351053 @default.
• W1999949526 hasAuthorship W1999949526A5081452175 @default.
• W1999949526 hasAuthorship W1999949526A5090577453 @default.
• W1999949526 hasConcept C126322002 @default.
• W1999949526 hasConcept C126894567 @default.
• W1999949526 hasConcept C141071460 @default.
• W1999949526 hasConcept C142724271 @default.
• W1999949526 hasConcept C204787440 @default.
• W1999949526 hasConcept C27081682 @default.
• W1999949526 hasConcept C2775854910 @default.
• W1999949526 hasConcept C2776312127 @default.
• W1999949526 hasConcept C2776541429 @default.
• W1999949526 hasConcept C2776548296 @default.
• W1999949526 hasConcept C2776886416 @default.
• W1999949526 hasConcept C2779329777 @default.
• W1999949526 hasConcept C2991744798 @default.
• W1999949526 hasConcept C43376680 @default.
• W1999949526 hasConcept C71924100 @default.
• W1999949526 hasConceptScore W1999949526C126322002 @default.
• W1999949526 hasConceptScore W1999949526C126894567 @default.
• W1999949526 hasConceptScore W1999949526C141071460 @default.
• W1999949526 hasConceptScore W1999949526C142724271 @default.
• W1999949526 hasConceptScore W1999949526C204787440 @default.
• W1999949526 hasConceptScore W1999949526C27081682 @default.
• W1999949526 hasConceptScore W1999949526C2775854910 @default.
• W1999949526 hasConceptScore W1999949526C2776312127 @default.
• W1999949526 hasConceptScore W1999949526C2776541429 @default.
• W1999949526 hasConceptScore W1999949526C2776548296 @default.
• W1999949526 hasConceptScore W1999949526C2776886416 @default.
• W1999949526 hasConceptScore W1999949526C2779329777 @default.
• W1999949526 hasConceptScore W1999949526C2991744798 @default.
• W1999949526 hasConceptScore W1999949526C43376680 @default.
• W1999949526 hasConceptScore W1999949526C71924100 @default.
• W1999949526 hasIssue "4" @default.
• W1999949526 hasLocation W19999495261 @default.
• W1999949526 hasLocation W19999495262 @default.
• W1999949526 hasOpenAccess W1999949526 @default.
• W1999949526 hasPrimaryLocation W19999495261 @default.
• W1999949526 hasRelatedWork W1978234349 @default.
• W1999949526 hasRelatedWork W1991922719 @default.
• W1999949526 hasRelatedWork W2051963354 @default.
• W1999949526 hasRelatedWork W2093371799 @default.

• next